These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22337655)

  • 41. Temporal expression of the PGE2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition.
    Frölich S; Olliges A; Kern N; Schreiber Y; Narumiya S; Nüsing RM
    Am J Physiol Renal Physiol; 2012 Jul; 303(2):F209-19. PubMed ID: 22573380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen.
    He S; Li C; Liu Y; Lai L
    J Med Chem; 2013 Apr; 56(8):3296-309. PubMed ID: 23527738
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel benzoxazole inhibitors of mPGES-1.
    Kablaoui N; Patel S; Shao J; Demian D; Hoffmaster K; Berlioz F; Vazquez ML; Moore WM; Nugent RA
    Bioorg Med Chem Lett; 2013 Feb; 23(3):907-11. PubMed ID: 23266122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HTRF-based assay for microsomal prostaglandin E2 synthase-1 activity.
    Goedken ER; Gagnon AI; Overmeyer GT; Liu J; Petrillo RA; Burchat AF; Tomlinson MJ
    J Biomol Screen; 2008 Aug; 13(7):619-25. PubMed ID: 18626113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potent inhibition of human 5-lipoxygenase and microsomal prostaglandin E₂ synthase-1 by the anti-carcinogenic and anti-inflammatory agent embelin.
    Schaible AM; Traber H; Temml V; Noha SM; Filosa R; Peduto A; Weinigel C; Barz D; Schuster D; Werz O
    Biochem Pharmacol; 2013 Aug; 86(4):476-86. PubMed ID: 23623753
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toward the discovery of new agents able to inhibit the expression of microsomal prostaglandin E synthase-1 enzyme as promising tools in drug development.
    De Simone R; Andrés RM; Aquino M; Bruno I; Guerrero MD; Terencio MC; Paya M; Riccio R
    Chem Biol Drug Des; 2010 Jul; 76(1):17-24. PubMed ID: 20492447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay.
    Langsdorf EF; Malikzay A; Lamarr WA; Daubaras D; Kravec C; Zhang R; Hart R; Monsma F; Black T; Ozbal CC; Miesel L; Lunn CA
    J Biomol Screen; 2010 Jan; 15(1):52-61. PubMed ID: 20019290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adiponectin stimulates prostaglandin E(2) production in rheumatoid arthritis synovial fibroblasts.
    Kusunoki N; Kitahara K; Kojima F; Tanaka N; Kaneko K; Endo H; Suguro T; Kawai S
    Arthritis Rheum; 2010 Jun; 62(6):1641-9. PubMed ID: 20222108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of a second generation of inhibitors of microsomal prostaglandin E synthase 1 expression bearing the gamma-hydroxybutenolide scaffold.
    Aquino M; Guerrero MD; Bruno I; Terencio MC; Paya M; Riccio R
    Bioorg Med Chem; 2008 Oct; 16(19):9056-64. PubMed ID: 18790649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol.
    Rörsch F; Wobst I; Zettl H; Schubert-Zsilavecz M; Grösch S; Geisslinger G; Schneider G; Proschak E
    J Med Chem; 2010 Jan; 53(2):911-5. PubMed ID: 20025212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostaglandin E(2) synthase inhibition as a therapeutic target.
    Iyer JP; Srivastava PK; Dev R; Dastidar SG; Ray A
    Expert Opin Ther Targets; 2009 Jul; 13(7):849-65. PubMed ID: 19530988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: use of a conformation-based hypothesis to facilitate compound design.
    Walker DP; Arhancet GB; Lu HF; Heasley SE; Metz S; Kablaoui NM; Franco FM; Hanau CE; Scholten JA; Springer JR; Fobian YM; Carter JS; Xing L; Yang S; Shaffer AF; Jerome GM; Baratta MT; Moore WM; Vazquez ML
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1120-6. PubMed ID: 23298810
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
    Koeberle A; Zettl H; Greiner C; Wurglics M; Schubert-Zsilavecz M; Werz O
    J Med Chem; 2008 Dec; 51(24):8068-76. PubMed ID: 19053751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
    Koeberle A; Rossi A; Zettl H; Pergola C; Dehm F; Bauer J; Greiner C; Reckel S; Hoernig C; Northoff H; Bernhard F; Dötsch V; Sautebin L; Schubert-Zsilavecz M; Werz O
    J Pharmacol Exp Ther; 2010 Mar; 332(3):840-8. PubMed ID: 19934399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.
    Xu D; Rowland SE; Clark P; Giroux A; Côté B; Guiral S; Salem M; Ducharme Y; Friesen RW; Méthot N; Mancini J; Audoly L; Riendeau D
    J Pharmacol Exp Ther; 2008 Sep; 326(3):754-63. PubMed ID: 18524979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mass spectrometry in high-throughput screening: a case study on acetyl-coenzyme a carboxylase using RapidFire--mass spectrometry (RF-MS).
    Jonas M; LaMarr WA; Ozbal C
    Comb Chem High Throughput Screen; 2009 Sep; 12(8):752-9. PubMed ID: 19531010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1.
    Wiegard A; Hanekamp W; Griessbach K; Fabian J; Lehr M
    Eur J Med Chem; 2012 Feb; 48():153-63. PubMed ID: 22209272
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression and purification of human mPGES-1 in E. coli and identification of inhibitory compounds from a drug-library.
    Kim WI; Choi KA; Do HS; Yu YG
    BMB Rep; 2008 Nov; 41(11):808-13. PubMed ID: 19017494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of a RapidFire mass spectrometry assay and a fluorescence assay for the discovery of kynurenine aminotransferase II inhibitors to treat central nervous system disorders.
    Lu H; Kopcho L; Ghosh K; Witmer M; Parker M; Gupta S; Paul M; Krishnamurthy P; Laksmaiah B; Xie D; Tredup J; Zhang L; Abell LM
    Anal Biochem; 2016 May; 501():56-65. PubMed ID: 26874021
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.
    Arhancet GB; Walker DP; Metz S; Fobian YM; Heasley SE; Carter JS; Springer JR; Jones DE; Hayes MJ; Shaffer AF; Jerome GM; Baratta MT; Zweifel B; Moore WM; Masferrer JL; Vazquez ML
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1114-9. PubMed ID: 23260349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.